The National Association of Specialty Pharmacy and the Specialty Pharmacy Association of America announced the merger of the two organizations, creating the largest professional and trade association focused on the unique needs in specialty pharmacy.
The Food and Drug Administration on Wednesday announced approval for Zydelig (idelalisib) to treat patients with chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic lymphoma.
The Food and Drug Administration on Thursday announced the approval of Ruconest, a recombinant C1-Esterase inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema.
Mylan on Thursday announced that the U.S. District Court for the district of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline in relation to paroxetine CR, the generic version of GSK's Paxil CR.
Former Republican Speaker of the House J. Dennis Hastert last week wrote an editorial for the Washington Times supporting the use of such tamper-resistant pseudoephedrine products as Acura Pharmaceuticals' Nexafed and Westport Pharmaceuticals' Zephrex-D.
Current programs to dispose of unused medicines in the home are sufficient, argued representatives of industry in appealing a provision put into place by a San Francisco-area county that would place the burden of recapturing these medicines on the manufacturer.
The National Association of Chain Drug Stores on Tuesday put forward pharmacy-specific solutions as the Senate Finance Committee conducted a hearing on “Chronic Illness: Addressing Patients’ Unmet Needs.”
Teva Pharmaceuticals on Monday announced that the Food and Drug Administration has accepted the company's new drug application for albuterol multi-dose dry-powder inhaler, a breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease.
Anacor Pharmaceuticals announced that the Food and Drug Administration has approved the company's new drug application for Kerydin (tavaborole) topical solution, 5% — an antifungal approved for the topical treatment of onychomycosis of the toenails.